Intellia's gene-editing treatment for angioedema faces FDA verdict in March 2027

Intellia Therapeutics has put a date on the first regulatory test of its in vivo CRISPR programme: the US Food and Drug Administration is aiming to act on the company's marketing application for lonvoguran ziclumeran, or lonvo-z, by 10 March 2027. The product, previously coded NTLA-2002, is being developed for hereditary angioedema (HAE).

The agency has accepted the biologics licence application and given it priority review, according to an investor presentation the company has published. Intellia also says the FDA has indicated it does not currently intend to convene an outside advisory committee. That position could change as the review proceeds.

The presentation goes beyond the filing news. It also covers results from the Phase 3 HAELO study and Intellia's preparations for a possible launch. The material available to us does not include the trial figures, pricing, or the detail of the launch plans, so none of those is reported here.

By way of context, priority review is an FDA designation that shortens the target review period for medicines that could offer a meaningful advance in serious conditions. The PDUFA date is the agency's goal for completing its action, not a guarantee of approval or of timing.